Abstract
Background During breastfeeding the macronutrient composition of breastmilk changes gradually from relatively low-fat (foremilk) to relatively high-fat (hindmilk), initially exposing the gastrointestinal tract to a relatively low fat concentration. In contrast, infant formulae (IF) are homogenous. Mild processing and addition of milk fat globule membrane (MFGM) may impact gastric emulsion instability, potentially impacting the phased release of nutrients as observed during breastfeeding.
Objective To assess gastric emulsion stability, gastric emptying, and the postprandial plasma metabolome of an experimental minimally processed IF (EF) with an altered fat-globule interface and a control IF (CF).
Methods Twenty healthy males participated in this double-blind randomized crossover trial. Gastric MRI scans and blood samples were obtained before and after consumption of 600 ml CF or EF over a 2-h period. Outcomes included gastric top layer formation, total gastric volume, and blood parameters (FFA, insulin, glucose, and NMR-metabolomics).
Results EF showed an earlier onset (13.4 min, p=0.017), smaller maximum volume (49.0 ml, p= 0.033), and a shorter time to maximum top layer volume (13.9 min, p=0.022), but similar AUC (p=0.915) compared to CF. Total gastric volume did not show a treatment*time effect. Insulin concentrations were lower for EF. FFA and glucose did not differ. EF yielded higher serum concentrations of phospholipid-and cholesterol-related metabolites.
Conclusion An EF displayed faster gastric creaming than a CF, thereby potentially better mimicking the behavior of breastmilk which leads to phased release of nutrients into the intestine. Overall physiological benefits of this difference in gastric behavior remain to be studied further in infants.
Competing Interest Statement
This study was funded by FrieslandCampina and Reina Tjoelker and Tim Lambers are employed by FrieslandCampina. The other authors declare no conflicts of interest
Clinical Trial
NCT05224947
Funding Statement
This study was funded by FrieslandCampina.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the involvement of human subjects in this study was granted by the Medical Ethical Committee of Wageningen University (Reference number: NL7 7717.091.21, dated November 1st, 2021).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Pubmed indexing: Roelofs JJM (julia.roelofs{at}wur.nl), Tjoelker RS (reina.tjoelker{at}frieslandcampina.nl), Lambers TT (tim.lambers{at}frieslandcampina.nl), Smeets PAM (paul.smeets{at}wur.nl)
Conflict of Interest and Funding Disclosure: Julia JM Roelofs: no conflicts of interest, Reina S. Tjoelker: employed at FrieslandCampina, Tim T. Lambers: employed at FrieslandCampina, Paul A.M. Smeets: no conflicts of interest
Source of support: FrieslandCampina
Ethical statement and registration: Ethical approval for the involvement of human subjects in this study was granted by the Medical Ethical Committee of Wageningen University (Reference number: NL7 7717.091.21, dated November 1st, 2021) and is in accordance with the Helsinki Declaration of 1975 as revised in 2013. This study was registered with clinicaltrials.gov under number NCT05224947.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
List of abbreviations
- BM
- Breast Milk
- BMI
- Body Mass Index
- FDR
- False Discovery Rate
- FFA
- Free Fatty Acids
- IF
- Infant Formula
- MFGM
- Milk Fat Globule Membrane
- MRI
- Magnetic Resonance Imaging
- NMR
- Nuclear Magnetic Resonance
- SGF
- Simulated Gastric Fluid